Only 4 of 40 patients underwent tumor rebiopsy, indicating the significant limitations and constraints associated with performing tumor rebiopsies in real-world clinical practice.31 Whereas it is well-known that approximately half of the acquired resistance to first-generation and second-generation EGFR TKIs is caused by EGFR T790M variants, in the current study, only 13% of patients (n = 5) had confirmed T790M variants as an acquired resistance mechanism.1 The low T790M detection rate in the current study is mostly attributed to the limited frequency of rebiopsies. This evidence concerns the gene EGFR and neoplasm.